文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

宫颈癌筛查指南、《子宫颈细胞学报告的贝塞斯达系统》及临床管理建议的更新

Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations.

作者信息

Wang Tiannan, Zhang Huina, Liu Yang, Zhao Chengquan

机构信息

Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.

出版信息

J Clin Transl Pathol. 2023 Jun;3(2):75-83. doi: 10.14218/jctp.2023.00004. Epub 2023 Apr 21.

DOI:10.14218/jctp.2023.00004
PMID:37456763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10348779/
Abstract

Over the past decades, cervical cancer has been a worldwide public health problem. Population-based early cancer risk detection and prevention approaches, including vaccination, cytology screening and human papilloma virus (HPV) detection, with the aligned clinical management, have formed a well-rounded high-quality implementation system for cervical cancer control, and revolutionarily improved the quality of life of women: (1) the success of cervical cancer screening practices, (2) standardization of The Bethesda system for reporting cervicovaginal cytology, (3) improvement in the understanding of HPV pathogenesis in cervical cancer, and (4) the development of appropriate management approaches have significantly decreased the disease burden of cervical cancer worldwide. This scoping review aimed to understand the evolvement of cervical cancer screening and management guidelines, describe the Bethesda cervical cytology reporting system, and HPV vaccines and tests, and highlight the key information of present policies and practices.

摘要

在过去几十年里，宫颈癌一直是一个全球性的公共卫生问题。基于人群的早期癌症风险检测和预防方法，包括疫苗接种、细胞学筛查和人乳头瘤病毒（HPV）检测，以及相应的临床管理，已经形成了一个全面的高质量宫颈癌防控实施体系，并彻底改善了女性的生活质量：（1）宫颈癌筛查实践的成功；（2）阴道镜细胞学报告的贝塞斯达系统的标准化；（3）对宫颈癌中HPV发病机制认识的提高；（4）适当管理方法的发展显著降低了全球宫颈癌的疾病负担。本综述旨在了解宫颈癌筛查和管理指南的演变，描述贝塞斯达宫颈细胞学报告系统、HPV疫苗和检测，并强调当前政策和实践的关键信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/b87ae5ee32ed/nihms-1895426-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/f54297685840/nihms-1895426-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/5d17f0308874/nihms-1895426-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/dde8b8a4d384/nihms-1895426-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/5cb446cddd70/nihms-1895426-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/9180daf1f101/nihms-1895426-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/b87ae5ee32ed/nihms-1895426-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/f54297685840/nihms-1895426-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/5d17f0308874/nihms-1895426-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/dde8b8a4d384/nihms-1895426-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/5cb446cddd70/nihms-1895426-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/9180daf1f101/nihms-1895426-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b3b/10348779/b87ae5ee32ed/nihms-1895426-f0006.jpg

相似文献

[1]
Updates in Cervical Cancer Screening Guidelines, The Bethesda System for Reporting Cervical Cytology, and Clinical Management Recommendations.

J Clin Transl Pathol. 2023-6

[2]

2011-5

[3]

2013-2-16

[4]
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Vaccine. 2013-12-31

[5]
The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.

Arch Pathol Lab Med. 2003-8

[6]
Anal dysplasia screening: an evidence-based analysis.

Ont Health Technol Assess Ser. 2007

[7]
Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

PLoS Med. 2017-9-19

[8]
Updates in Cervical Cytology: The 90-Year-Long Journey from Battle Creek to Today.

Surg Pathol Clin. 2018-9

[9]
Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Arch Med Res. 2009-8

[10]
Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.

BMC Med. 2023-2-10

引用本文的文献

[1]
Prevalence of high-grade cervical intraepithelial neoplasia in Mexican women aged under 40 years: a cross-sectional study.

J Turk Ger Gynecol Assoc. 2025-9-3

[2]
CINtec PLUS: A Novel Alternative Screening Method for Detecting High-Risk Cervical Lesions in Romania.

Cureus. 2024-9-11

[3]
Comprehensive overview of genotype distribution and prevalence of human papillomavirus in cervical lesions.

Gynecol Obstet Clin Med. 2024-4

[4]
Analysis of atypical glandular cells in ThinPrep Pap smear and follow-up histopathology.

Proc (Bayl Univ Med Cent). 2024-3-21

[5]
AI-assisted system improves the work efficiency of cytologists via excluding cytology-negative slides and accelerating the slide interpretation.

Front Oncol. 2023-11-23

本文引用的文献

[1]
High-risk HPV testing improves accuracy in detection of CIN2+ lesions in ASC-H postmenopausal women? An academic hospital experiences.

J Am Soc Cytopathol. 2023

[2]
Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

J Low Genit Tract Dis. 2021-10-1

[3]
Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.

CA Cancer J Clin. 2020-9

[4]
2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

J Low Genit Tract Dis. 2020-4

[5]
Safety of the 9-Valent Human Papillomavirus Vaccine.

Pediatrics. 2019-11-18

[6]
A review of the FDA-approved molecular testing platforms for human papillomavirus.

J Am Soc Cytopathol. 2019

[7]
Safety of Human Papillomavirus Vaccines: An Updated Review.

Drug Saf. 2018-4

[8]
Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials.

J Immunol Res. 2017-7-24

[9]
Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States.

Hum Vaccin Immunother. 2016-6-2

[10]
The Pap test and Bethesda 2014.

Cancer Cytopathol. 2015-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索